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Abstract 
Prothrombin time (PT) is the leading test
for  monitoring  oral  anticoagulation  therapy
(OAT).  According  to  the  World  Health
Organization  recommendation,  International
Normalized Ratio (INR) results obtained from
the same patient samples with the major PT
methods  (Quick  and  Owren)  should  be  the
same when the therapeutic range is the same.
In our study blood samples were obtained from
207  OAT  patients.  We  analyzed  the  samples
using two Quick and two Owren PT (combined
thromboplastin)  reagents  for  INR  and
assessed the sensitivity and true coagulation
activity  using  a  new-generation  PT  method.
The INR values with the Quick PT and Owren
PT methods were very similar around the nor-
mal  range,  while  unacceptable  differences
were seen within the therapeutic range and at
higher INR values. The Quick PT results as
INR  are  clearly  lower  than  those  given  by
Owren PT and the difference increases toward
higher INR. The new PT method functions well
with both Owren PT reagents, and we can cal-
culate the true active INR. The Quick PT meth-
ods show no sensitivity to coagulation inhibi-
tion measurement. The harmonization of the
INR is an important goal for the safety of OAT
patients.  More  accurate  INR  results  reduce
morbidity and mortality, and the therapeutic
ranges  should  be  similar  worldwide.  In  this
study  we  found  unacceptable  differences  in
INR results produced by the two PT methods.
The new method showed a lack of sensitivity to
Quick PT. For the global harmonization of OAT
therapy and for INR accuracy only the more
sensitive Owren PT method should be used.
Introduction
Oral anticoagulation therapy (OAT) is one of
the most commonly used medications world-
wide. The purpose of the treatment is to bal-
ance the risks of hemorrhage and thrombosis
in the patient. Arterial and venous complica-
tions commonly are involved in morbidity and
mortality in OAT patients globally.
1-4 The vita-
min K antagonists coumarin and warfarin are
inexpensive and the most widely used medi-
cines  in  the  prevention  and  treatment  of
thromboembolism  in  various  clinical  situa-
tions, and the benefit of OAT has been proved.
5-12
The major drawback with warfarin is a narrow
therapeutic window and individually variable
responses to the treatment. Thus frequent pro-
thrombin  time  (PT)  checks  are  required  to
ensure  that  anticoagulation  remains  within
the  therapeutic  range,  which  is  2.0-3.0
International Normalized Ratio (INR).
New  medications  for  oral  anticoagulation
therapy have been developed over a number of
years and anticipated without laboratory test
control in an effort to replace warfarin. The
new  medicines,  however,  have  not  proved
superior to warfarin. The new molecules are
expensive and involve serious side effects or
only narrow indications for OAT.
13
According to a recent review,
14,15 prothrom-
bin time has served as a basis for OAT moni-
toring since its first description by Quick more
than  70  years  ago.  PT  measures  vitamin  K-
dependent coagulation factors II, VII, and X.
3,4
Warfarin  (VKAs)  inhibits  the  synthesis  of
coagulation factors II, VII, IX, and X in the liver,
which remain partially inactive unless nine to
13  of  the  amino-terminal  glutamate  (Glu)
residues are carboxylated to form Ca
2+-binding
γ-carboxyglutamate (Gla) residues.
3,4 Thus it is
inevitable that the more medication is admin-
istered, the more inactive coagulation factors
will result, hampering and inhibiting the PT
measurement.
Today, two major PT methods are accepted
for anticoagulant medication control and they
are used globally for chronic anticoagulation
checks: either the Quick PT, which is based on
the technique described by Quick and his col-
leagues in 1935,
14,15 or the Owren PT
16 (com-
bined thromboplastin reagent). The Owren PT
is  the  predominant  approach  used  in  the
Nordic countries, the Benelux, and Japan. The
accuracy and comparability of PT results are
essential to the safety of the individual in anti-
coagulant therapy and to improve the applica-
bility of anticoagulation guidelines. The World
Health Organization (WHO) recommendation
for the use of INR given in the mid-1980s was
aimed to harmonize PT results for OAT, regard-
less of the laboratory, reagent, instrument, or
method used.
17,18
Unfortunately,  an  increasing  body  of  evi-
dence  indicates  that  this  goal  has  not  been
achieved.
19-26
Different reagents are known to vary with
respect to the source of thromboplastins and
other  reagent  components,
26 and  these  have
not been characterized in detail. The Owren
method  is  reagarded  as  the  “reference
method” in which fibrinogen and factor V are
added to the reagent, and these do not depend
on K-vitamin antagonists. The Quick PT meas-
ures both of these coagulation factors, which
is a drawback in OAT control. In the Owren
method  the  sample  volume  in  the  reaction
mixture is 5% only, in the Quick method 33%.
On account of this difference in sample dilu-
tion the Owren PT is considered to be a more
sensitive method than the Quick PT. 
In the present study, we sought to compare
INR results for warfarin therapy from the same
OAT patient samples using both the Owren and
the Quick PT methods. The aim was to study
the method and reagent sensitivity of Owren
and  Quick  PT  using  the  new-generation  PT
method developed by Horsti et al., which can
measure active coagulation without inhibition
from inactive coagulation factors.
13,27,28
Materials and Methods
Patients and blood sampling
Venous blood samples were obtained from
207  hospital  and  health-center  patients
referred to the PT test for the monitoring of
oral anticoagulant therapy. In our region a “P-
INR” test code is used for this purpose. Hence,
the  patient  samples  represented  all  possible
phases of anticoagulation: pretreatment, dose-
adjusting  phase,  and  steady-state  phase.  All
the procedures were approved by the responsi-
ble committee of our institution in accordance
with  the  Helsinki  Declaration  of  1975.  The
blood (3.15 mL) was drawn into citrate coagu-
lation  tubes  (Greiner  Labortechnik  GmbH,
Vacuette cat. No. 454332, 9NC) containing 0.35
mL  0.109  mol/L  (3.2%)  citrate  solution.  The
sample  needle  (Terumo,  Venoject  needle,
Quick Fit, cat. No. MN-2138MQ) was 0.8x40
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1850 g for 10 min at 20°C to separate the plas-
ma. All the measurements were commenced
within eight hours from blood collection.
Prothrombin time determination
The  calculation  formula  is  for  the
International Normalized Ratio: INR = (sam-
plesec/normalsec)
ISI, where ISI is the International
Sensitivity Index. When ISI is close to 1.0, the
reagent is sensitive and ISI is insignificant in
the INR calculation. The PT coagulation times
were measured using a fully automated ACL
TOP  CTS  coagulation  analyzer  (Instrument-
ation Laboratory, IL, Lexington, MA, USA). For
the  Owren  PT  (combined  thromboplastin
reagent)  the  coagulation  reaction  contained
10 µL of citrated sample plasma, 60 µL of dilu-
ent, and 140 µL of reagent. The volumes for
“dilution measurement” were 5 µL + 65 µL +
140 µL. The test reagents were Nycotest PT,
cat. No. 1002488 (rabbit brain thromboplastin)
and  diluent  (Nycotest  PT,  dilution  liquid,
cat.No.  999002)  from  Axis-Shield  as
lot.10132661, ISI=1.12; Owren's PT, cat.no. GHI
131-10  (rabbit  thromboplastin),  and  diluent
(Owren's  buffer,  cat.No.  GHI  150)  from
Medirox as lot 75051, ISI=1.16. For the one-
stage prothrombin time with Quick, 100 µL of
coagulation reagent was added to 50 µL of cit-
rated plasma. Sample volumes for the dilution
were 100 µL + 25 µL + 25 µL (Factor Diluent,
HemosIL,  cat.no.  0009757600  from  IL).  The
test reagents were: RecombiPlasTin 2 G cat.
No.  0020003050  (recombinant  human  tissue
thromboplastin)  from  Instrumentation
Laboratory, Lexington USA as lot. N0486316,
ISI=0.97;  PT-Fibrinogen  HS  PLUS  cat.  no.
0008469810  (rabbit  brain  thromboplastin)
from  Instrumentation  Laboratory,  Lexington
USA as lot. N0185573 ISI=1.11.
Additional reagents
Control  Plasma  Normal  cat.No.  1002387
from Axis-Shield as lot. 1D71AOA, NKP Normal
Control Plasma cat.No. GHI 162 from MediRox
AB as lot. 72011, and Normal Control Assayed
cat.No. 0020003110 from IL as lot. N0386069.
The new-generation prothrombin
time method 
We constructed PT (sec) vs. C (C = plasma
or calibrator dilution factor) plots for normal
and OAT plasmas. This is consistent with an
uncompetitive  inhibition  principle  with  oral
anticoagulants. From the line equation the y-
axis  intercept  is  calculated.  This  is  the  so-
called minimal clotting time (tmin) with an infi-
nite number of clotting factors. The difference
in intercepts (y-axis) between normal plasma
and OAT plasma indicates the action of uncom-
petitive inhibition in seconds without a cali-
bration effect. We went on to calculate the dif-
ference  in  intercepts  also  in  INR  units  and
subtracted this from total INRTot (more expla-
nation about the new method in reference 28
[patent pending for PT method]),
27,28
INRAct = INRTot  – INRInh
INRs were calculated using the formula INR =
(samplesec / normalsec)
ISI
The dilution factor for the Owren PT and
Quick PT was 2.0.
Analytical imprecision and statistics
The within-run precision of the PT tests was
measured using normal plasma (n = 10 deter-
minations).  The  respective  CVs  were:  for
Nycotest  PT  1.81%;  Owren's  PT  0.90%;
RecombiPlasTin 2 G 0.55%; PT-Fibrinogen HS
PLUS 2.15%, and pooled plasma (about 2 INR):
for  Nycotest  PT  1.26%;  Owren's  PT  1.14%;
RecombiPlasTin 2 G 1.07%; PT-Fibrinogen HS
PLUS  1.94%.  The  Microsoft  Excel  5.0  and
Analyse-it for Microsoft Excel from Analyse-it
Software Ltd programs were used to obtain the
correlation functions and INR results.
Results
We compared the results of four different
commercial INR determination methods (two
Quick PT and two Owren PT, ISI values 0.97;
1.11 and 1.12; 1.16) from 207 blood samples
from patients in imminent or ongoing OAT. All
the ISI values used for reagents were manufac-
turer values. The INR values obtained with the
different  methods  were  similar  around  the
normal range or INR 1 (Figure 1). In contrast,
marked differences were seen in the therapeu-
tic  range  (2-3  INR)  and  higher  INR  values
between the Quick PT and Owren PT methods.
The INRs produced by the Quick PT are clearly
lower than those given by the Owren PT, and
the difference increases toward higher INRs.
Using correlation equations between the four
methods,  the  differences  were  calculated
applying the Microsoft Excel 5.0 and Passing &
Bablok  method  comparison,  Analyse-it  for
Microsoft Excel from Analyse-it Software Ltd
programs (Table 1).
The difference between the Owren PT meth-
ods in INR terms is below 10% over the whole
measuring range. In the therapeutic range, the
average difference is 0.16 INR; 6.10%. The dif-
ference between Nycotest PT and Pt-Fib HS is
8.03-15.75% and in the therapeutic range an
average  of  0.23  INR;  8.6%.  The  difference
between Nycotest PT and Recomb 2G is 0.74-
27.43% and in the therapeutic range an aver-
age of 0.49 INR; 19.0%. 
The Owren methods showed excellent corre-
lation (y = 0.96x + 0.052; intercept 95% CL
0.034 to 0.071; slope 0.948 to 0.973), while the
correlations  between  Quick  and  Owren  PT
were  not  good:  Nyco  PT  vs.  Pt-FibHS  (y  =
0.7955x + 0.2802; intercept 95% CL 0.242 to
0.319; slope 0.769 to 0.823), and Nyco PT vs.
Rec 2G (y = 0.669x + 0.3357; intercept 95% CL
0.290 to 0.381; slope 0.642 to 0.700). The corre-
lation was not good either between the Quick
methods: Pt-FibHS vs. Rec 2G (y = 0.8267x +
0.1055, non-linear relationship; intercept 95%
CL 0.063 to 0.150; slope 0.800 to 0.857).
The  new-generation  PT  method  functions
well  with  the  two  Owren  PT  methods  and
makes it possible to calculate the true active
INR without inhibition (Figure 2). The correc-
tion lowers the INR values closer to Quick PT
values.  Marked  individual  differences  were
seen  in  the  therapeutic  range  2-3  INR  and
higher values between Rec 2 G INR (Quick PT)
and Owren's PT INRACT (Owren PT) (Figure
3). The correlation between active INR results
is good (y = 0.8955x + 0.104; intercept 95% CL
0.087 to 0.122; slope 0.885 to 0.907). The Quick
PT methods show no sensitivity to the coagula-
tion inhibition measurement.
Discussion
The global harmonization of INR and thera-
peutic ranges for different clinical indications
is an important goal for the benefit of patients
[page 88] [Hematology Reviews 2009; 1:e15]
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Table 1. Differences in INR results between four PT methods at variable INR levels as
INR units and percentages. The correlation equations between methods were used for the
calculations.
Nycotest Owren's Diff  Diff  PT-Fib Diff  Diff  Reco  Diff  Diff 
PT INR PT INR % INR INR % INR 2G INR % INR
1,00 1,00 0,05 0,00 1,08 8,03 - 1,01 0,74 -
0,08 0,01
2,00 1,90 5,25 0,11 1,88 6,23 0,12 1,68 16,16 0,32
3,00 2,79 6,98 0,21 2,67 10,99 0,33 2,35 21,79 0,65
4,00 3,69 7,85 0,31 3,47 13,37 0,53 3,02 24,61 0,98
5,00 4,58 8,37 0,42 4,26 14,79 0,74 3,69 26,30 1,32
6,00 5,48 8,72 0,52 5,06 15,75 0,94 4,35 27,43 1,65[Hematology Reviews 2009; 1:e15] [page 89]
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Figure  1.  INR  values  in
increasing order from 207 ana-
lyzed patient samples on anti-
coagulation  therapy.  Nycotest
PT and Owren's PT are Owren
methods (combined thrombo-
plastin  reagent),  and  PT-
FibHS and Rec 2G are Quick
methods.
Figure  2.  INRTOT and  INRACT
values in increasing order from
207  analyzed  patient  samples
on  anticoagulation  therapy.
Owren's  PT  reagent  (com-
bined thromboplastin reagent)
and  the  new-generation  PT
method  are  used  for  INR
measurement.
Figure 3. Rec 2G, Quick PT,
INR,  and  Owren's  PT  (com-
bined thromboplastin reagent)
INRACT  values  in  increasing
order  from  207  analyzed
patient samples on anticoagu-
lation therapy. The new-gener-
ation  PT  method  is  used  for
INRACT measurement. [page 90] [Hematology Reviews 2009; 1:e15]
as well as clinicians. WHO originally envisaged
INR as a reliable and safe method for obtaining
results  from  anticoagulation  trials  and  as  a
basis  for  expert  guidelines  for  treatment.
However, the results of earlier studies and this
present study demonstrate that the goal has
not  been  achieved.  The  narrow  therapeutic
range and the increase in complications and
mortality outside this range call for the devel-
opment of more accurate laboratory analytics.
A  computer  simulation  study  of  serial  INR
measurements has been conducted within the
most widely used therapeutic range (INR 2.0 -
3.0);  the  authors  concluded  that  analytical
imprecision should be <5% and analytical bias
< ± 0.2 INR units.
29
In this study, agreement between the Quick
PT  and  Owren  PT  methods  was  particularly
poor  and  failed  to  meet  the  qualification
requirements.  For  this  study  we  selected  a
newly developed recombinant PT reagent, but
the result was not acceptable. We may wonder
whether the difference in sample volume in
the reaction mixture (5% and 33%) accounts
for the measurement sensitivity. Both Owren
PT reagents are sensitive to inactive coagula-
tion  factor  measurement  (inhibition),  while
the Quick PT reagents are not.
In our earlier study we used DadeBehring
Innovin with human placenta thromboplastin
(Quick PT reagent), which is the most sensi-
tive reagent to inactive coagulation factors and
inhibition.  The  sensitivity  thus  does  not
depend  only  on  differences  in  principle
between the Quick PT or Owren PT methods.
The  thromboplastin  and  other  components
used in the reagent affect the reagent sensitiv-
ity. Horsti
24 has compared the Quick PT and
Owren PT methods for the harmonization of
INR results and concluded that Quick PT yields
clinically  divergent  and  Owren  PT  clinically
acceptable INR results. It would be interesting
to study the effect of lupus anticoagulants on
Quick PT and Owren PT methods. The results
of recent studies, unfortunately, demonstrate
that  attempts  at  harmonization  have  to
improve.
25 The unacceptable situation for oral
anticoagulation was confirmed further by this
present investigation.
How can the harmonization of INR results
be improved worldwide? For global use, WHO
should recommend only the Owren PT, which
is  the  superior  method.  The  advantages  of
Owren PT are the fact that it measures only
vitamin K-dependent coagulation factors F II, F
VII, and F X (not fibrinogen and F V), and pro-
vides greater sensitivity and extensive dilution
of  the  interfering  matrix  substances  in  the
final reaction mixture.
19,25 The patient samples
also contain inactive coagulation factors, the
amount of which increases concomitant with
increased anticoagulant medication and high-
er  INR  levels,  interfering  with  and  causing
error  in  the  coagulation  measurement.  The
inhibition depends on the medication and the
patient's individual metabolism, and thus each
patient’s sample must be corrected individual-
ly.
27,28 The Owren PT methods are sensitive, but
more susceptible to the inactive coagulation
factors and inhibition in measurement. In an
earlier  study  we  measured  only  the  active
coagulation factors, INRAct(F II, F VII, FX) with-
out inhibition, which provided a new possibili-
ty to develop anticoagulant therapy and more
appropriate care for OAT patients. The active
coagulation factors are responsible for throm-
bosis  or  bleeding  in  vivo  and  medication
should  be  based  on  this  principle.
13,27,28 The
inhibition interferes with the calibration pro-
cedure and measurement. 
This study was conducted from the point of
view  of  a  clinical  laboratory  without  clinical
data and outcomes are missing between meth-
ods  (Quick  PT,  Owren  PTTOT,  Owren  PTACT),
which would give the final answer as to the
superiority of PT methods. This study revealed
the lack of sensitivity in both Quick PT meth-
ods but good sensitivity and correlation in the
Owren PT activity (INRAct) measurements. The
editorials of Clinical Chemistry have posed the
critical question and sought answers: “Has the
Time  Arrived  to  Replace  the  Quick
Prothrombin  Time  Test  for  Monitoring  Oral
Anticoagulant  Therapy?”
19 On  the  basis  of
recent studies and our opinion we can answer:
“Yes, with the Owren PT without inhibition.”
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